Den Europæiske Union - dansk - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - narkotika anvendt i diabetes - diabetes mellitus hvor behandling med insulin er påkrævet. insuman rapid er også egnet til behandling af hyperglykæmisk koma og ketoacidose samt for at opnå præ-, intra- og postoperativ stabilisering hos patienter med diabetes mellitus.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - epoetin alfa - injektionsvæske, opløsning i fyldt injektionssprøjte - 10.000 ie/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - epoetin alfa - injektionsvæske, opløsning i fyldt injektionssprøjte - 2.000 ie/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - epoetin alfa - injektionsvæske, opløsning i fyldt injektionssprøjte - 40.000 ie/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - epoetin alfa - injektionsvæske, opløsning i fyldt injektionssprøjte - 4.000 ie/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

b. braun melsungen - natriumchlorid - infusionsvæske, opløsning - 9 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

mip pharma gmbh - citronsyre, vandfri, kaliumchlorid, macrogol 4000, natriumchlorid, natriumcitratdihydrat - koncentrat til oral opløsning

Den Europæiske Union - dansk - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulants, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

fresenius medical care deutschland gmbh - calciumchloriddihydrat, glucosemonohydrat, magnesiumchloridhexahydrat, natriumchlorid, natriumlactat opløsning - peritonealdialysevæske - 1,5 %+1,25 mmol/l